Canadian psychedelic company Numinus Wellness partnered with the Multidisciplinary Association for Psychedelic Studies (MAPS) to support psychedelic experiential opportunities for practitioners within a clinical study.
Pending approval of its Clinical Trial Application (CTA) by Health Canada, Numinus will have exclusive rights to conduct a clinical trial for practitioners interested in MDMA-assisted therapy. The trial will allow practitioners to observe and participate in MDMA sessions to enhance their understanding of psychedelic-assisted therapy.
The clinical trial will employ clinical-grade MDMA manufactured by Optimi, a licensed Canadian company specializing in producing and supplying psychedelic substances for clinical trials. Initially, Numinus intends to conduct the trial at its clinics in Vancouver, with potential expansion to other locations in the future.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.